Reported 1 day ago
The U.S. FDA has approved an injectable formulation of Bristol Myers Squibb's cancer medication Opdivo, enhancing convenience for patients previously reliant on IV infusions. Branded Opdivo Qvantig, it is indicated for adult solid tumors and priced similarly to its IV counterpart, which faces impending patent expiration. This new version, using innovative delivery technology, is expected to sustain sales growth amidst the company's evolving portfolio.
Source: YAHOO